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Background. Infections caused by the pandemic H1N1 2009 influenza virus range from mild upper respiratory
tract syndromes to fatal diseases. However, studies comparing virological and immunological profile of different
clinical severity are lacking.
Methods. We conducted a retrospective cohort study of 74 patients with pandemic H1N1 infection, including
23 patients who either developed acute respiratory distress syndrome (ARDS) or died (ARDS-death group), 14
patients with desaturation requiring oxygen supplementation and who survived without ARDS (survived-without-
ARDS group), and 37 patients with mild disease without desaturation (mild-disease group). We compared their
pattern of clinical disease, viral load, and immunological profile.
Results. Patients with severe disease were older, more likely to be obese or having underlying diseases, and
had lower respiratory tract symptoms, especially dyspnea at presentation. The ARDS-death group had a slower
decline in nasopharyngeal viral loads, had higher plasma levels of proinflammatory cytokines and chemokines,
and were more likely to have bacterial coinfections (30.4%), myocarditis (21.7%), or viremia (13.0%) than patients
in the survived-without-ARDS or the mild-disease groups. Reactive hemophagocytosis, thrombotic phenomena,
lymphoid atrophy, diffuse alveolar damage, and multiorgan dysfunction similar to fatal avian influenza A H5N1
infection were found at postmortem examinations.
Conclusions. The slower control of viral load and immunodysregulation in severe cases mandate the search
for more effective antiviral and immunomodulatory regimens to stop the excessive cytokine activation resulting
in ARDS and death.
Instead of the anticipated influenza A pandemic with
a viral antigenic shift of the surface hemagglutinin sub-
types from the seasonal H3 and H1 to either H2 or H5
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[1], a swine origin influenza A H1N1 virus is now
replacing the seasonal H1N1 as the cause of the present
pandemic. Although such antigenic change is expected
to be associated with clinical severity due to the general
lack of neutralizing antibody, the crude mortality rate
in developed countries was comparable to seasonal in-
fluenza. Despite that the majority of the deaths were
associated with major underlying illnesses, the higher
rate of severe disease in the younger age sector merits
more investigations [2]. Moreover, this new virus ap-
peared to have recently jumped from swine to human
[3] and replicated more efficiently in the lower respi-
ratory tract of laboratory mammals when compared
 at University of Hong Kong on January 18, 2011
cid.oxfordjournals.org
D
ow
nloaded from
 
Viral and Immunological Profile of H1N1 • CID 2010:50 (15 March) • 851
with the recent seasonal influenza A H1N1 viruses [4–6]. Al-
though smoking, pregnancy, and morbid obesity were being
highlighted as important risk factors for complications in severe
cases [7–9], the pathogenesis has not been investigated by serial
viral load and immunological studies as in the case of fatal
influenza A H5N1 infections, which had persistently high viral
load and marked proinflammatory cytokine activation [10, 11].
During the initial containment phase of this pandemic H1N1
2009 influenza epidemic in Hong Kong, all known infected
patients were compulsorily isolated in hospitals, which pro-
vided the opportunity of taking serial clinical samples [12]. We
compared the clinical progression; viral load, cytokine, and
chemokine levels; and histopathological findings of labora-
tory-confirmed cases of different clinical severity. Their impli-
cations on the pathogenesis and treatment were discussed.
PATIENTS AND METHODS
Patients. Seventy-four patients, who were admitted to hos-
pitals in Hong Kong between May and September 2009 and
tested positive for pandemic H1N1 2009 influenza virus, were
included in the study. Twenty-three patients either developed
acute respiratory distress syndrome (ARDS) and/or died
(ARDS-death group). In this group, 13 patients (56.5%) died
and 18 (78.3%) developed ARDS. Another group of 14 patients
developed oxygen desaturation to !90% while breathing room
air and required respiratory support, but survived and without
developing ARDS (survived-without-ARDS group). Thirty-
seven patients isolated in the hospital during this period with-
out respiratory decompensation were randomly selected to rep-
resent the mild-disease group.
Methods. This study was approved by the institutional re-
view board of the Hospital Authority of Hong Kong. Clinical
findings including history and physical examination, oximet-
ric measurement, hematological, biochemical, radiological, and
microbiological investigation results were entered into a pre-
designed database. Their acute physiology and chronic health
evaluation II scores were recorded [13]. ARDS and multior-
gan dysfunction syndrome were defined with standard criteria
[14–15]. We observed all groups until death or discharge from
hospital.
All 74 patients had the diagnosis of pandemic H1N1 2009
influenza virus infection confirmed either when the pandemic
H1 gene was tested positive by reverse-transcription polymerase
chain reaction (RT-PCR) or by viral culture in nasopharyngeal
or endotracheal specimens. All laboratory procedures were per-
formed as previously reported [16]. Serial nasopharyngeal, and
if intubated, endotracheal viral load, were assessed by quanti-
tative PCR of the influenza A virus M gene [17]. The detection
limit of this assay was 900 copies of RNA/mL. Blood, urine,
and fecal samples were also tested. Oseltamivir resistance was
directly detected in the initial positive nasopharyngeal or en-
dotracheal sample by RT-PCR and sequencing of a 320-bp
fragment of the neuraminidase gene spanning the 274 position
for a CrT mutation [18]. The test was repeated in respiratory
specimens of patients with persistently high viral load despite
oseltamivir treatment. All initial respiratory tract samples were
cultured in Madin Darby Canine Kidney cell line with trypsin
for 7 days.
The respiratory tract samples on admission were also assessed
by multiplex PCR (Luminex) with ResPlex II v2.0 assay (Qia-
gen) for coinfection with respiratory syncytial virus, influenza
B virus, parainfluenza viruses 1–4, human metapneumovirus,
enteroviruses, rhinovirus, adenovirus, bocavirus, and corona-
viruses NL63, HKU1, 229E, and OC43, in accordance with
manufacturer’s instructions; and by PCR for Mycoplasma
pneumoniae and Chlamydophila pneumoniae [19, 20]. We in-
vestigated blood, sputum or endotracheal aspirates, and urine
samples bacteriologically, as clinically indicated. Initial urine
samples were tested for pneumococcal and legionella antigen
by immunochromatographic enzyme immunoassay (Binax).
The host immunological response was monitored by the Lu-
minex enzyme immunoassay (Luminex) for 25 different plasma
cytokines and chemokines.
Statistical analysis. Clinical, virological, and immunolog-
ical characteristics were compared. The Fisher exact test and
x2 test were used for categorical variables where appropriate,
and the Mann-Whitney U test was used for continuous vari-
ables because the data was not normally distributed. Signifi-
cant risk factors for severe diseases were not further ana-
lyzed by multiple logistic regressions due to the small number
of cases. Linear regression was used to assess the trend of mean
viral load. The Jonckheere-Terpstra trend test was used to com-
pare cytokine or chemokine level with clinical severity. Pear-
son correlation was used to assess the relationship between the
viral load and the absolute lymphocyte count or plasma cyto-
kine levels. SPSS software, version 17.0 for Windows (SPSS),
was used for statistical computation. P values !.05 were con-
sidered to represent statistically significant differences.
RESULTS
Patients in ARDS-death group were significantly older and
more likely to be obese or to have underlying diseases than
mild-disease group (Table 1). Lower respiratory tract symp-
toms, especially dyspnea, were more common at presentation
in ARDS-death group. Comparison between patients in ARDS-
death and survived-without-ARDS group did not reveal sig-
nificant differences in terms of demographic characteristics,
presenting symptoms, and vital signs on admission, except that
wheezing was more common in survived-without-ARDS group.
Chronic pulmonary disease was more common in survived-
without-ARDS group than ARDS-death group. Overall, 93.2%
of patients received oseltamivir, but nebulized zanamivir was
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Table 1. Demographic Characteristics and Underlying Comorbidities
Characteristic
ARDS-death
group
(n p 23)
Survived-without-ARDS
group
(n p 14) Pa
Mild-disease
group
(n p 37) Pb
Demographic characteristic
Age, median years (range) 49 (23–84) 52 (30–79) .199 21 (15–53) !.001
Ratio of male to female patients 13:10 10:4 .365c 14:23 .157c
Obesity (BMI, 127) 4 (17.4) 6 (42.9) .132 0 (0) .018
Pregnancy 1 (4.3) 0 (0) 1.99 0 (0) .383
Underlying diseased
No underlying disease 6 (26.1) 2 (14.3) .683 35 (94.6) !.001c
Chronic heart disease 3 (13.0) 4 (28.6) .390 0 (0) .052
Chronic pulmonary disease 4 (17.4) 9 (64.3) .006 2 (5.4) .191
Diabetes mellitus 1 (4.3) 4 (28.6) .057 0 (0) .383
Presenting symptoms
Feverishness 18 (78.3) 8 (57.1) .268 31 (83.8) .734
Cough 22 (95.7) 14 (100) 1.99 27 (73.0) .039
Sputum 13 (56.5) 10 (71.4) .365c 8 (21.6) .006c
Sore throat 9 (39.1) 5 (35.7) .835c 23 (62.2) .082c
Wheezing 5 (21.7) 8 (57.1) .039 0 (0) .006
Myalgia/ arthralgia 5 (21.7) 3 (21.4) 1.99 10 (27.0) .646c
Dyspnea 21 (91.3) 14 (100) .517 1 (2.7) !.001c
Vomiting 4 (17.4) 0 (0) .276 0 (0) .018
Diarrhea 2 (8.7) 1 (7.1) 1.99 3 (8.1) 1.99
Exacerbation of underlying disease
COAD 3 (13.0) 3 (21.4) .654 0 (0) .052
Asthma 0 (0) 6 (42.9) .001 0 (0) NA
Vital signs on presentation
Hypotensione 9 (39.1) 1 (7.1) .056 0 (0) !.001
Pulse, 1100 beats/min 15 (65.2) 10 (71.4) 1.99 9 (24.3) .002c
Respiratory rate 120 breaths/min 14 (60.9) 9 (64.3) .835c 0 (0) !.001c
Temperature, 138C 10 (40.3) 4 (28.6) .365c 23 (62.2) .157c
Duration of symptoms before admission, median days (range) 5 (0–12) 3.5 (0–11) .229 1 (0–4) !.001
Duration of hospitalization, median days (range) 14 (1–69) 10 (4–27) .398 7 (2–11) .025
NOTE. Data are no. (%) of patients, unless otherwise indicated. For statistical analysis, Mann Whitney U-test was used for continuous variables,
whereas the Fisher exact test was used for categorical variables unless otherwise indicated. ARDS, acute respiratory distress syndrome; BMI, body
mass index (calculated as weight in kilograms divided by the square of height in meters); NA, not available.
a Comparison between ARDS-death and survived-without-ARDS groups.
b Comparison between ARDS-death and mild-disease groups.
c By x2 test.
d For ARDS-death group, other underlying comorbidities included hypertension (in 5 patients), cerebrovascular disease (in 3), malignancy (in 3),
chronic liver disease (in 2), epilepsy (in 1), thalassemia trait (in 1), and hypothyroidism (in 1). For the survived-without-ARDS group, other comorbidities
include hypertension (in 5 patients), chronic liver disease (in 1), chronic renal disease (in 1), thalassemia trait (in 1), and eczema (in 1).
e Systolic blood pressure, !90 mm Hg; or diastolic blood pressure, !60 mm Hg.
only used in patients with more severe diseases. The median
time for initiation of oseltamivir treatment was 5 days after
symptom onset in the ARDS-death group, which is later than
4 days in the survived-without-ARDS group and 2 days in the
mild-disease group. Three patients in the ARDS-death group
did not receive oseltamivir because the diagnosis was made
after death. Empirical antibiotics were started in all patients in
the ARDS-death and survived-without-ARDS group on ad-
mission. The regimen was modified according to bacteriological
test results or on an individual basis.
As for the initial laboratory parameters at presentation (Table
2), neutrophil count, serum alanine transaminase (ALT), cre-
atine kinase, and lactate dehydrogenase levels were higher, but
the absolute lymphocyte count was lower in the ARDS-death
group than the mild-disease group. ARDS-death group also
had a significantly lower total white blood cell, neutrophil, and
platelet counts and ALT levels than the survived-without-ARDS
group. The nasopharyngeal ( ; ) and en-2r p 0.0386 Pp .009
dotracheal ( ; ) viral loads inversely corre-2r p 0.1461 P ! .001
lated with the concomitant absolute lymphocyte count.
Initial nasopharyngeal and endotracheal viral loads were sim-
ilar among patients with different disease severity (Table 3).
Peak viral load occurred within 2 days after symptom onset
(Figure 1A). Nasopharyngeal viral load decreased after osel-
tamivir therapy, with the slowest decrease in the ARDS-death
group (Figure 1B). Viremia was found by RT-PCR in 3 patients
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Table 2. Investigations, Treatments, Complications, and Clinical Outcomes
Variable
ARDS-death
group
(n p 23)
Survived-without-ARDS
group
(n p 14) P a
Mild-disease
group
(n p 37) P b
Initial laboratory findings, median (range)
Total white blood cell count,  109 cells/L 5.1 (0.8–28.0) 9.0 (4.5–13.4) .011 5.3 (2.88.4) .994
Neutrophil count, 109 cells/L 3.9 (0.4–21.7) 7.0 (3.3–13.2) .017 3.2 (1.1–7.2)c .046
Lymphocyte count, 109 cells/L 0.6 (0.2–2.8) 0.65 (0.3–1.8) .758 1.2 (0.5–2.6)c !.001
Platelet count, 109 platelets/L 178 (68–310) 225 (117–352) .036 194 (111–329) .063
Alanine transaminase level, IU/L 45 (13–167) 17 (11–61) .010 18 (5–45)c !.001
Creatinine level, mmol/L 76 (46–628) 79.5 (49–236) .851 67 (42–115) .052
Creatine kinase level, IU/L 221 (20–1561) 127 (55–5077) .562 73 (42–623)d .017
Lactate dehydrogenase level, IU/L 474 (157–1154) 398 (163–2246) .346 194 (135–344)e !.001
Clinical outcome
Mechanical ventilationf 22 (95.7) 4 (28.6) !.001 0 (0) !.001g
ICU admission 21 (91.3) 7 (50) .014 0 (0) !.001g
Median APACHE II score (range)h 22 (0–42) 15 (7–34) .405 NA NA
Antiviral treatment data
Oseltamivir treatment 20 (87.0) 14 (100) .275 35 (94.6) .362
Duration of symptoms before starting oseltamivir, median days (range) 5 (1–13) 4 (0–11) .307 2 (0–5) !.001
Nebulized zanamivir 15 (65.2) 1 (7.1) .001g 0 (0) !.001g
Duration of symptoms before starting zanamivir, median days (range) 7 (1–15) 5 (5–5) .828 NA NA
Complications
Progression of infiltrates to all 4 quadrants on chest radiograph 11 (47.8) 4 (28.6) .247 0 (0) !.001
Bacterial coinfection on presentation 7 (30.4) 2 (14.3) .434 0 (0) .001
Ventilator-associated pneumonia 4 (17.4)i 0 (0) .276 NA NA
Pulmonary embolism 1 (4.3) 0 (0) 1.99 0 (0) .383
Acute pulmonary edema 0 (0) 2 (14.3) .137 0 (0) NA
Myocarditis 5 (21.7) 0 (0) .135 0 (0) .006
Pericardial effusion 4 (17.4) 1 (7.1) .135 0 (0) .018
Acute renal failure requiring renal replacement therapy 6 (26.1) 0 (0) .065 0 (0) .002
Multiorgan dysfunction syndrome 16 (69.6) 1 (7.1) !.001g 0 (0) !.001g
Inotropic support 18 (78.3) 2 (14.3) !.001g 0 (0) !.001g
NOTE. Data are no. (%) of patients, unless otherwise indicated. For statistical analysis, the Mann Whitney U test was used for continuous
variables, and the Fisher exact test was used for categorical variables, unless otherwise indicated. APACHE, Acute Physiology and Chronic Health
Evaluation; ARDS, acute respiratory distress syndrome; COAD, chronic obstructive airway disease; ICU, intensive care unit; NA, not applicable.
a Comparison between ARDS-death and survived-without-ARDS groups.
b Comparison between ARDS-death and mild-disease groups.
c Data are for 36 patients.
d Data are for 18 patients.
e Data are for 23 patients.
f Patients who did not undergo mechanical ventilation. One patient in the ARDS-death group and 4 patients in the survived-without-ARDS
group received bi-level positive airway pressure support only, and 3 patients in the ARDS-death group received extracorporeal membrane
oxygenation.
g By x2 square test.
h Only for patients admitted to the ICU.
i Included methicillin-resistant Staphylococcus aureus, methicillin-susceptible S. aureus, Klebsiella species, Citrobacter species, Enterobacter
species, Pseudomonas aeruginosa, and Acinetobacter species.
in the ARDS-death group and 1 patient in the survived-with-
out-ARDS group. Only 1 stool sample, from a patient in the
survived-without-ARDS group, had positive RT-PCR results.
All urine samples tested negative by RT-PCR. Oseltamivir re-
sistance with H274Y mutant existing as quasi-species in 3 dif-
ferent specimens were found in 1 patient in the survived-with-
out-ARDS group.
Of the 25 cytokines or chemokines assayed, significantly
higher levels of granulocyte colony-stimulating factor (G-CSF),
interferon (IFN)–a2, interleukin (IL)–1a, IL-6, IL-8, IL-10, IL-
15, IFN-g–induced protein 10 (IP-10), monocyte chemoat-
tractant protein (MCP)–1, and tumor necrosis factor (TNF)–
a were found in the initial samples of ARDS-death group than
mild-disease group (Table 3). Initial IL-17 levels were lower in
the ARDS-death group than in the mild-disease group, with
the difference approaching statistical significance ( ).Pp .074
Compared with the survived-without-ARDS group, signifi-
cantly higher levels of G-CSF, IL-1a, IL-6, IL-10, IL-15, MCP-
1, and TNF-a were found in ARDS-death group. When strat-
ified according to days after symptom onset (days 0–3, days
4–6, and days 7–10), only IL-6, IL-10, and IL-15 levels were
higher in those with more severe disease throughout all 3 pe-
riods, whereas G-CSF, IL-1a, IL-8, IP-10, and TNF-a levels
were higher only during later phase of the disease (Figure 2A–
2K).
Coinfections on presentation occurred in ARDS-death and
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Table 3. Initial Plasma Cytokine or Chemokine Levels and Viral Load in Respiratory Specimens
Variable
ARDS-death
group
(n p 18)
Survived-without-ARDS
group
(n p 10) P a
Mild-disease
group
(n p 29) P b
Cytokine or chemokine, log10 pg/mL
c,d
G-CSF 2.11 (1.33–3.91) 1.13 (0.19–2.03) !.001 1.31 (0.74–2.43) !.001
IFN-a2 1.1 (0.71–2.49) 0.79 (0.71–1.79) .138 0.71 (0.71–2.07) .024
IL-1a 2.13 (1.38–2.78) 1.66 (1.17–2.19) .014 1.59 (0.94–2.46) !.001
IL-6 2.40 (1.32–4.00) 1.19 (0.81–1.97) !.001 0.08 (0.08–2.14) !.001
IL-8 2.25 (1.23–4.02) 1.70 (1.18–3.20) .084 1.21 (0.78–2.66) !.001
IL-10 1.80 (1.14–2.70) 1.02 (0.19–2.36) .002 0.48 (0.19–1.60) !.001
IL-15 0.92 (0.44–1.70) 0.33 (0.20–2.36) !.001 0.20 (0.20–0.65) !.001
IL-17 0.20 (0.20–2.94) 0.20 (0.20–0.87) .298 0.76 (0.20–2.48) .074
IP-10 3.83 (3.01–4.01) 3.10 (2.69–4.01) .065 3.00 (1.80– 3.36) !.001
MCP-1 3.11 (2.48–3.74) 2.73 (2.41–3.44) .017 2.58 (1.94–3.00) !.001
TNF-a 1.19 (0.62–2.12) 0.90 (0.89–1.15) .002 0.86 (0.80–1.25) !.001
Viral load, log10 copies/mL
e
Nasopharyngealf 5.45 (2.65–7.49) 5.68 (2.65–8.65) .817 5.97 (2.65–10.7) .484
Endotrachealg 4.97 (2.65–7.16) 5.24 (4.83–5.86) .369 NA NA
Note:Data are presented as median (range). Mann-Whitney U-test was used for statistical analysis. ARDS, acute respiratory distress syndrome;
G-CSF, granulocyte colony-stimulating factor; IFN, interferon; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; NA, not applicable;
TNF, tumor necrosis factor.
a Comparison between ARDS-death and survived-without-ARDS groups.
b Comparison between ARDS-death and mild-disease groups.
c The detection limit of the assay was 3.1 pg/mL for G-CSF, 10.16 pg/mL for IFN-a2, 17.31 pg/mL for IL-1a, 2.41 pg/mL for IL-6, 3.19 pg/
mL for IL-8, 3.10 pg/mL for IL-10, 3.17 pg/mL IL-15, 3.15 pg/mL for IL-17, 2.69 pg/mL for IP-10, 3.33 pg/mL for MCP-1, and 3.21 pg/mL TNF-
a.
d Other cytokines or chemokines tested were granulocyte-macrophage colony-stimulating factor, IFN-g, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-7, IL-
12(p40), IL-12(p70), IL-13, macrophage inflammatory protein 1a, macrophage inflammatory protein 1b, and TNF-b.
e The initial nasopharyngeal samples were collected at a median of 4 days after symptom onset for the ARDS-death group (range, 0–13
days), 4 days (range, 0–10 days) for survived-without-ARDS group, and 2 days (range, 0–8 days) for mild cases. The initial endotracheal samples
were collected at a median of 6 days (range, 1–12 days) for the ARDS-death group and 7 days (range, 7–12 days) for the survived-without-
ARDS group after symptom onset.
f Data are for 17 patients in the ARDS-death group, 13 patients in the survived-without-ARDS group, and 37 patients in the mild-disease
group.
g Data are for 16 patients in the ARDS-death group and 3 patients in the survived-without-ARDS group.
survived-without-ARDS groups (Table 2). Among ARDS-death
group, community-acquired methicillin-resistant Staphylococ-
cus aureus was cultured from blood and pleural fluid samples
from 1 patient and from sputum samples from another patient.
Methicillin-susceptible S. aureus and Pseudomonas species were
cultured from 2 and 1 patient respectively. One patient had
pulmonary tuberculosis, with a sputum smear positive for acid-
fast bacilli and PCR positive for Mycobacterium tuberculosis.
This same patient also had pneumococcal antigenuria. For sur-
vived-without-ARDS group, Haemophilus influenzae and Pseu-
domonas species were found in 1 patient each. Rhinovirus was
detected in 2 patients from ARDS-death group and 1 patient
from survived-without-ARDS group. Other respiratory viruses,
C. pneumoniae, M. pneumoniae, and Legionella species were not
detected.
Complications were most common in the ARDS-death group
(Table 2). Five patients (21.7%) had clinical, laboratory, and
echocardiographic evidence of myocarditis; 3 of these cases
were confirmed at postmortem examination (Figure 3E). Mul-
tiorgan dysfunction syndrome predominantly occurred in
ARDS-death group (69.6%). One patient in the ARDS-death
group developed both ventilator associated pneumonia and En-
terobacter cloacae bacteremia. No rhabdomyolysis or enceph-
alopathy was found.
The median time of death was 10 days after symptom onset
(range, 3–33 days). The cause of death was respiratory failure
in 11 patients (including 5 patients with secondary bacterial
pneumonia, 4 patients with myocarditis), heart failure due to
myocarditis in 1 patient, and Escherichia coli bacteremia in 1
patient. Postmortem examination or paramortem tissue bi-
opsies were performed in 5 patients who died between day 3
and 28 after symptom onset. Examination of 4 patients who
died around day 10 after symptom onset showed acute exu-
dative diffuse alveolar damage with proteinaceous exudate in
alveolar space and interstitial infiltrate in alveolar septa (Figure
3A). One patient, who died on day 28 after symptom onset,
had fibroproliferative changes of diffuse alveolar damage (Fig-
ure 3B). Reactive hemophagocytosis was found in the lymph
node or bone marrow of 2 patients (Figure 3F). Lymphoid
atrophy was also observed (Figure 3D). Three cases had changes
of acute lymphocytic myocarditis (Figure 3E). One case had
thrombosis in branches of pulmonary artery (Figure 3C) and
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Figure 1. Nasopharyngeal viral load in patients with different clinical severity, according to number of days after symptom onset (A) and to number
of days after initiation of oseltamivir treatment (B). Horizontal dotted line indicates detection limit of reverse-transcription polymerase chain reaction.
ARDS, acute respiratory distress syndrome.
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Figure 2. Plasma cytokine or chemokine level, stratified by days after symptom onset. Median, quartiles, and range are shown. The Jonckheere-
Terpstra trend test was used to compare cytokine level with disease severity. Horizontal dotted line, detection limit of the assay. A, Granulocyte
colony-stimulating factor. B, Interferon (IFN)–a2. C, Interleukin (IL)–1a. D, IL-6. E, IL-8. F, IL-10. G, IL-15. H, IL-17. I, IFN-g–induced protein 10. J,
Monocyte chemoattractant protein–1. K, Tumor necrosis factor-a.
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Figure 3. Histopathological changes of pulmonary and extrapulmonary tissue (hematoxylin-eosin stained) of the deceased patients suffering from
pandemic influenza A H1N1 2009. A, Lung parenchyma showing acute exudative phase of diffuse alveolar damage on day 7 after symptom onset in
a 42-year-old previously healthy man with interstitial cellular infiltrate and proteinaceous exudates in alveoli and hyaline membrane formation (original
magnification, 100). B, Lung parenchyma showing chronic fibroproliferative phase of diffuse alveolar damage with marked thickening of the alveolar
septa and alveolar space being replaced by fibrogranulation tissues on day 28 of symptom onset in a 37-year-old previously healthy woman (original
magnification, 200). C, Thrombosis of branches of pulmonary artery in the same patient in panel B who died despite extracorporeal membrane
oxygenation (original magnification, 200). D, Lymphoid atrophy with no recognizable germinal centre in the spleen of the same patient in panels B
and C. The periarteriolar lymphoid sheath (white pulp), which was markedly reduced in size (original magnification, 400). E, Myocardium showing
a microscopic focus of lymphoid aggregate accompanied by myofibril necrosis in a 58-year-old man presenting with elevated creatine kinase isoenzyme
CK-MB and echocardiographic evidence of diastolic dysfunction (original magnification, 200). F, Mediastinal lymph node showing reactive hemo-
phagocytosis in the same patient in panel E (original magnification, 400).
splenic artery with wedge-shaped infarct despite heparinization
while undergoing extracorporeal membrane oxygenation.
DISCUSSION
Clinical studies on the severity of pandemic H1N1 2009 influ-
enza virus infection have not utilized patients with mild disease
except for pregnant patients [8]. Laboratory study in cell lines
showed that this virus was similar to recent seasonal influenza
A H1N1 virus in terms of viral replication rate and the ability
to induce proinflammatory cytokines but markedly inferior to
that of influenza A H5N1 virus [11, 21]. However, unlike sea-
sonal influenza virus, which replicates mainly in the upper
respiratory tract, challenge studies in mammals showed that
the pandemic virus can replicate to a high level in both the
upper and lower respiratory tracts [4–6]. The findings of ARDS
with postmortem findings of diffuse alveolar damage, reactive
hemophagocytosis and lymphoid atrophy in our deceased pa-
tients were compatible with a cytokine storm and have similarly
been reported in H5N1 infection [10]. Therefore, we studied
the clinical characteristics, serial viral load in the respiratory
specimens, and plasma levels of cytokines and chemokines in
the 3 groups of patients with different levels of disease severity.
Irrespective of disease severity, the viral load already peaked
within 2 to 3 days of symptom onset. Animal experiments and
clinical studies showed that viral load increased steadily within
48 h after inoculation when the host failed to mount any innate
immune response [22]. Once innate immune response was
mounted, the viral load reached a plateau. Due to the later
presentation of the severe cases, data on the viral load in the
initial days after symptom onset were scarce. Thus, the naso-
pharyngeal viral load at presentation appeared to be slightly
lower in the more severe groups. The later presentation of the
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more severe cases might have allowed more time for the re-
cruitment of cytotoxic T lymphocyte response specific to the
highly homologous nucleoprotein antigen present in all influ-
enza A viruses which can suppress the viral load.
A slower decline in viral shedding was observed in all severe
patients in the ARDS-death group or the survived-without-
ARDS group than in the mild-disease group (Figure 1A and
1B). The finding could be related to a less effective innate and
adaptive immune response together with a delay in starting
antiviral therapy due to a later presentation. Fatal cases of H5N1
infection had persistently high viral load due to oseltamivir
resistance [23], but oseltamivir resistance was not responsible
for the slower rate of decline in viral shedding in our series,
because only 1 patient was infected with oseltamivir-resistant
virus who eventually survived without complication by ARDS.
Although uncontrolled viral infection was unlikely to be the on-
ly cause of death or ARDS, antiviral therapy that can suppress
the viral load more rapidly, such as intravenous zanamivir [24],
and neutralizing antibody in convalescent plasma or hyper-
immune intravenous immunoglobulin should be considered in
randomized, control trials for the treatment of severe cases.
Such strategy may accelerate clearance of their viral load, which
may also reduce the excessive cytokine release.
As for the role of proinflammatory cytokines or chemokines,
which can have both antiviral activity and damage on host tissue,
highest levels were seen in the ARDS-death group. Plasma cy-
tokine and chemokine profiles of the severe group were consistent
with the challenged macaque model, which showed elevated lev-
els of MCP-1 and IL-6 in their inflamed lungs [6]. When stratified
by time after symptom onset, there was a significant correlation
between disease severity and the level of IL-6, IL-10, and IL-15
throughout the initial 10 days after symptom onset. Correlation
between higher IL-6 levels and severe influenza infection has been
well established in both animal and in human [26–27], but this
correlation has not been reported for IL-10 and IL-15. As an
anti-inflammatory cytokine, IL-10 is essential in dampening in-
flammatory response to prevent excessive host damage. Of in-
terest, IL-10 deficiency was shown to be protective in influenza
infection in mice, and high IL-10 production in elderly was
associated with poorer antibody response to influenza vaccine
[27, 28]. IL-15 level has been reported to be elevated among
many bacterial and viral infections [29]. Despite being regarded
as a proinflammatory cytokine, recent animal model suggested
that high levels of IL-15 may actually decrease the level of
antibody against influenza [30]. In contrast, IL-17 was lower
in the more severe groups, consistent with previous studies
which showed that IL-17 might help to protect against lethal
influenza [31]. The use of immunomodulator in the treatment
of influenza is still controversial but appeared effective when
an antiviral is given concomitantly [32].
In our series, lymphopenia was more common among pa-
tients with severe disease, as seen in SARS coronavirus infection
[33]. Furthermore, an inverse correlation between lymphocyte
count and viral load in both the nasopharyngeal and endotra-
cheal specimens was observed. Similar findings were found in
patients with H5N1 infection [26]. Lymphopenia in infection
may be due to lymphocyte apoptosis mediated by TNF-a,
which was also elevated. Another possibility was direct infec-
tion of T lymphocytes, as shown in histopathological studies
of H5N1 infection [34].
Evidence of bacterial coinfection was present in 30.4% of
our most severe cases, which resembled the rate in another
autopsy study [35]. However, bacterial isolates in our series
have been covered adequately during the course of hospitali-
zation. Other nonpulmonary complications, such as myocar-
ditis, might have contributed to the mortality. Chronic pulmo-
nary diseases and exacerbation of underlying pulmonary co-
morbidities were over-represented in the survived-without-
ARDS group, suggesting that although these patients required
oxygen supplementation, their prognosis was usually better
than those who have respiratory decompensation due to viral
pneumonitis. Thrombotic phenomena such as thrombosis in
branches of pulmonary artery and splenic artery leading to
wedged splenic infarct were found, which resembled those re-
ported during the 1918 pandemic [36]. Although abdominal
symptoms were reported to be an important clinical manifes-
tation, and although an in vitro study showed that this virus
could replicate to a high level in the intestinal cell line Caco-
2 [21], gastrointestinal symptoms were not prominent in our
cases. As in patients who developed cytokine storm, shock re-
quiring inotropic support and multiorgan dysfunction syn-
drome were frequent.
Our study had several limitations. The frequent taking of
clinical samples was prohibitive to the enrollment of children,
and even adult patients occasionally refused serial nasopha-
ryngeal or blood sampling. Viral load can be affected by minor
differences in sampling technique, but this problem will affect
all groups. The use of nasopharyngeal swabs may result in a
lower viral load than nasopharyngeal aspirate, but very few of
our samples were obtained by swabs. Because of the changing
clinical status of individual patients, treatment regimen could
not be unified and may confound the viral load and immu-
nological profiles. In summary, a slower control of viral load
and dysregulated cytokine profile are important in the path-
ogenesis of severe disease by this new pandemic virus. Preex-
isting immune impairment due to underlying diseases or ge-
netic susceptibility in apparently immunocompetent cases
should be investigated. Our findings mandate interventional
studies of severe cases by other antiviral and immunomodu-
latory strategies.
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